

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Subject code for form 144B/RTD

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Give as many details as possible and

Shop

10

U.S. PATENT DOCUMENTS

Application Number	10/661,780
Filing Date	09/15/2003
First Named Inventor	PHILIPPE BOUCHARD
Art Unit	1614
Examiner Name	Brian Yong S. Kwon
Attorney Docket Number	098501-0305968

U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Case No.*	Foreign Patent Document Country Code* Number* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

Examiner Signature	Date Considered	
-----------------------	--------------------	--

\*EXAMINER: Initial Filing considered, whether or not claimed is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 001.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. 6 Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.57 and 1.68. The information is required to obtain or retain a benefit by the public which is to be furnished by the USPTO to prevent abuse of the system. Completion of this collection is estimated to take 2 hours to complete. The time for responding, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments or remarks on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, US Department of Commerce, P.O. Box 1499, Alexandria, VA 22313-1450. DOD SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. FAX NUMBER: 703-305-3700. Complainants for Petitions, P.O. Box 1499, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

3

## Completes if Known

Application Number	10/661,780
Filing Date	09/15/2003
First Named Inventor	PHILIPPE BOUCHARD
Art Unit	1614
Examiner Name	Brian Yong S. Kwon
Attorney Docket Number	098501-0305998

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		NESTOR, JR. ET AL., "Potent gonadotropin releasing hormone antagonists with low histamine-releasing activity," J. Med. Chem., Institute of Bio-Organic Chemistry, Vol. 35 (No. 21), p. 3942-3948, (October 16, 1992).	
		DEGHENGHII ET AL., "Antarelix (EP 24332) a novel water soluble LHRH antagonist," Biomed. Pharmacother., Europeptides (Argenteuil, France), Vol. 47 (No. 2-3), p. 107-110, (1993).	
		RIVIER ET AL., "Gonadotropin-releasing hormone antagonists with N omega-triazolylomobutine, -lysine, or -p-aminophenylalanine residues at positions 5 and 6," J. Med. Chem., Salk Institute for Biological Studies (La Jolla, California ), Vol. 35 (No. 23), p. 4270-4278, (November 13, 1992).	
See Attachment 1		HAVIV ET AL., "In vitro and in vivo activities of reduced-size antagonists of luteinizing hormone-releasing hormone," J. Med. Chem., TAP Pharmaceuticals, Inc. (Abbott Park, IL), Vol. 37 (No. 5), p. 701-705, (March 4, 1994).	
		WEBNBAUER ET AL., "Comparison of the antagonidotropic activity of three GnRH antagonists (Nal-Glu, Antide and Cetrorelix) in a non-human primate model (Macaca fascicularis)," Andrologia, Institute of Reproductive Medicine of the University (Munster, Germany), Vol. 25 (No. 3), p. 141-147, (May-June 1993).	

Examiner Signature	Date Considered

\*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. Including gathering, preparing, and maintaining the data in the system. Response times will vary depending upon the individual case. Any comments including gathering, preparing, and maintaining the data in the system. Response times will vary depending upon the individual case. Any comments including gathering, preparing, and maintaining the data in the system. Response times will vary depending upon the individual case.

USPTO is not responsible for the return of incomplete forms. DO NOT SEND FEES OR COMPLETED FORMS TO THE USPTO. ADDRESS: SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## Addendum

Page 3 of 3

### Attachment 1

- a.
- b. STOECKEMANN ET AL., "Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoc013) and the LHRH agonist buscerein or dimethylbenz[*J*]anthracene-induced mammary carcinoma: studies with slow-release formulations," *J. Cancer Res. Clin. Oncol.*, Hoechst AG, Pharma-Research (Frankfurt/Main, Germany), Vol. 119 ( No. 8), p. 457-462, (1993).
- c.